RU2011152007A - Варианты натрийуретического пептида с-типа - Google Patents
Варианты натрийуретического пептида с-типа Download PDFInfo
- Publication number
- RU2011152007A RU2011152007A RU2011152007/10A RU2011152007A RU2011152007A RU 2011152007 A RU2011152007 A RU 2011152007A RU 2011152007/10 A RU2011152007/10 A RU 2011152007/10A RU 2011152007 A RU2011152007 A RU 2011152007A RU 2011152007 A RU2011152007 A RU 2011152007A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- cnp
- cnp27
- cnp22
- cnp37
- Prior art date
Links
- 108020001621 Natriuretic Peptide Proteins 0.000 title abstract 2
- 102000004571 Natriuretic peptide Human genes 0.000 title abstract 2
- 239000000692 natriuretic peptide Substances 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 claims abstract 31
- 101800000060 C-type natriuretic peptide Proteins 0.000 claims abstract 31
- 101800000433 CNP-53 Proteins 0.000 claims abstract 6
- UHSBKBYWHCBDCJ-DYGWFTAGSA-N natriuretic peptide, c-type Chemical compound N1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CN)CSSC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H]1CC1=CC=CC=C1 UHSBKBYWHCBDCJ-DYGWFTAGSA-N 0.000 claims abstract 6
- 101800000459 CNP-29 Proteins 0.000 claims abstract 3
- 102400001026 CNP-29 Human genes 0.000 claims abstract 3
- 101800000419 CNP-38 Proteins 0.000 claims abstract 3
- 101800000420 CNP-39 Proteins 0.000 claims abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 238000000034 method Methods 0.000 claims 13
- 101000788172 Homo sapiens Transcription initiation factor TFIID subunit 12 Proteins 0.000 claims 12
- 102100025171 Transcription initiation factor TFIID subunit 12 Human genes 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 206010058314 Dysplasia Diseases 0.000 claims 7
- 210000000988 bone and bone Anatomy 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 230000004927 fusion Effects 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- 239000000090 biomarker Substances 0.000 claims 5
- 210000000845 cartilage Anatomy 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 206010008723 Chondrodystrophy Diseases 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 102000000503 Collagen Type II Human genes 0.000 claims 2
- 108010041390 Collagen Type II Proteins 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000005065 achondrogenesis Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims 2
- 201000010072 hypochondroplasia Diseases 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000002464 muscle smooth vascular Anatomy 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 102000016284 Aggrecans Human genes 0.000 claims 1
- 108010067219 Aggrecans Proteins 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 101800000457 CNP-22 Proteins 0.000 claims 1
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 claims 1
- 208000009447 Cardiac Edema Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 108010022452 Collagen Type I Proteins 0.000 claims 1
- 102000012422 Collagen Type I Human genes 0.000 claims 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 206010013883 Dwarfism Diseases 0.000 claims 1
- 108010013369 Enteropeptidase Proteins 0.000 claims 1
- 102100029727 Enteropeptidase Human genes 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049933 Hypophosphatasia Diseases 0.000 claims 1
- 102000004195 Isomerases Human genes 0.000 claims 1
- 108090000769 Isomerases Proteins 0.000 claims 1
- 241001523179 Lasia <small-headed fly> Species 0.000 claims 1
- 206010024503 Limb reduction defect Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 208000011262 Micromelia Diseases 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 claims 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 201000001718 Roberts syndrome Diseases 0.000 claims 1
- 208000020221 Short stature Diseases 0.000 claims 1
- 102100036407 Thioredoxin Human genes 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 208000008919 achondroplasia Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 201000007845 atelosteogenesis Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000007394 diastrophic dysplasia Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000011426 mesomelic dysplasia Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 201000010809 spondyloepimetaphyseal dysplasia Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 108060008226 thioredoxin Proteins 0.000 claims 1
- 229940094937 thioredoxin Drugs 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
1. Вариант натрийуретического пептида С-типа (CNP), выбранный из группы, состоящей из:GDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP53) (SEQ ID NO: 179);PDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP53) (SEQ ID NO: 185);MDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP53) (SEQ ID NO: 190);DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP-53(M48N)] (SEQ ID NO: 180);LRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-52) (SEQ ID NO: 146);RVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-51) (SEQ ID NO: 147);VDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-50) (SEQ ID NO: 148);DTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-49) (SEQ ID NO: 149);TKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-48) (SEQ ID NO: 150);KSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-47) (SEQ ID NO: 151);SRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-46) (SEQ ID NO: 152);RAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-45) (SEQ ID NO: 153);AAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-44) (SEQ ID NO: 154);AWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-43) (SEQ ID NO: 155);WARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-42) (SEQ ID NO: 156);ARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-41) (SEQ ID NO: 157);RLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-40) (SEQ ID NO: 158);LLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-39) (SEQ ID NO: 159);LQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-38) (SEQ ID NO: 160);QEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-37) (SEQ ID NO: 60);EHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-36) (SEQ ID NO: 161);HPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-35) (SEQ ID NO: 162);PNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-34) (SEQ ID NO: 163);NARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-33) (SEQ ID NO: 164);ARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-32) (SEQ ID NO: 165);RKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-31) (SEQ ID NO: 166);KYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-30) (SEQ ID NO: 167);YKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-29) (SEQ ID NO: 168);KGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-28) (SEQ ID NO: 169);GANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-27) (SEQ ID NO: 170);ANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-26) (SEQ ID NO: 171);NKKGLSKGCFGLKLDRIGSMSGLGC (CNP-25) (SEQ ID NO: 172);KKGLSKGCFGLKLDRIGSMSGLGC (CNP-24) (SEQ ID NO: 173);KGLSKGCFGLKLDRIGSMSGLGC (CNP-23) (SEQ ID NO: 174);LSKGCFGLKLDRIGSMSGLGC (CNP-21) (SEQ ID NO: 175);SKGCFGLKLDRIGSMSGLGC (CNP-20) (SEQ ID NO: 176);KGCFGLKLDRIGSMSGLGC (CNP-19) (SEQ ID NO: 177);GCFGLKLDRIGSMSGLGC (CNP-18) (SEQ ID NO: 178);QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP37(M32N)] (SEQ ID NO: 182);PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP37) (SEQ ID NO: 186);MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP37) (SEQ ID NO: 192);GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP37) (SEQ ID NO: 75);GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [Gly-CNP37(M32N)] (SEQ ID NO: 181);PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-
Claims (20)
1. Вариант натрийуретического пептида С-типа (CNP), выбранный из группы, состоящей из:
GDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP53) (SEQ ID NO: 179);
PDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP53) (SEQ ID NO: 185);
MDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP53) (SEQ ID NO: 190);
DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP-53(M48N)] (SEQ ID NO: 180);
LRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-52) (SEQ ID NO: 146);
RVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-51) (SEQ ID NO: 147);
VDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-50) (SEQ ID NO: 148);
DTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-49) (SEQ ID NO: 149);
TKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-48) (SEQ ID NO: 150);
KSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-47) (SEQ ID NO: 151);
SRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-46) (SEQ ID NO: 152);
RAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-45) (SEQ ID NO: 153);
AAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-44) (SEQ ID NO: 154);
AWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-43) (SEQ ID NO: 155);
WARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-42) (SEQ ID NO: 156);
ARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-41) (SEQ ID NO: 157);
RLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-40) (SEQ ID NO: 158);
LLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-39) (SEQ ID NO: 159);
LQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-38) (SEQ ID NO: 160);
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-37) (SEQ ID NO: 60);
EHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-36) (SEQ ID NO: 161);
HPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-35) (SEQ ID NO: 162);
PNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-34) (SEQ ID NO: 163);
NARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-33) (SEQ ID NO: 164);
ARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-32) (SEQ ID NO: 165);
RKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-31) (SEQ ID NO: 166);
KYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-30) (SEQ ID NO: 167);
YKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-29) (SEQ ID NO: 168);
KGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-28) (SEQ ID NO: 169);
GANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-27) (SEQ ID NO: 170);
ANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-26) (SEQ ID NO: 171);
NKKGLSKGCFGLKLDRIGSMSGLGC (CNP-25) (SEQ ID NO: 172);
KKGLSKGCFGLKLDRIGSMSGLGC (CNP-24) (SEQ ID NO: 173);
KGLSKGCFGLKLDRIGSMSGLGC (CNP-23) (SEQ ID NO: 174);
LSKGCFGLKLDRIGSMSGLGC (CNP-21) (SEQ ID NO: 175);
SKGCFGLKLDRIGSMSGLGC (CNP-20) (SEQ ID NO: 176);
KGCFGLKLDRIGSMSGLGC (CNP-19) (SEQ ID NO: 177);
GCFGLKLDRIGSMSGLGC (CNP-18) (SEQ ID NO: 178);
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP37(M32N)] (SEQ ID NO: 182);
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP37) (SEQ ID NO: 186);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP37) (SEQ ID NO: 192);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP37) (SEQ ID NO: 75);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [Gly-CNP37(M32N)] (SEQ ID NO: 181);
PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-Gly-CNP37) (SEQ ID NO: 145);
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-Gly-CNP37) (SEQ ID NO: 145);
GHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (HSA-CNP27) (SEQ ID NO: 144);
GHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSNSGLGC [HSA-CNP27(M22N)] (SEQ ID NO: 183);
PGHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-HSA-CNP27) (SEQ ID NO: 188);
MGHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-HSA-CNP27) (SEQ ID NO: 193);
GANRRGLSRGCFGLKLDRIGSMSGLGC [CNP27(K4,5,9R)] (SEQ ID NO: 36);
GANRRGLSRGCFGLKLDRIGSNSGLGC [CNP27(K4,5,9R, M22N)] (SEQ ID NO: 184);
PGANRRGLSRGCFGLKLDRIGSMSGLGC [Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189);
MGANRRGLSRGCFGLKLDRIGSMSGLGC [Met-CNP27(K4,5,9R)] (SEQ ID NO: 194);
ПЭГ1К-GANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭГ1К-CNP27(K4,5,9R)] (SEQ ID NO: 36);
ПЭГ1К-GANRRGLSRGCFGLKLDRIGSNSGLGC [ПЭГ1К-CNP27(K4,5,9R, M22N)] (SEQ ID NO: 184);
ПЭГ1К-PGANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭГ1К-Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189);
ПЭГ1К-MGANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭГ1К-Met-CNP27(К4,5,9R)] (SEQ ID NO: 194);
ПЭО12-GANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭО12-CNP27(К4,5,9R)] (SEQ ID NO: 36);
ПЭО12-GANRRGLSRGCFGLKLDRIGSNSGLGC [ПЭО12-CNP27(К4,5,9R, M22N)] (SEQ ID NO: 184);
ПЭО12-PGANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭО12-Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189);
ПЭО12-MGANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭО12-Met-CNP27(K4,5,9R)] (SEQ ID NO: 194);
ПЭО24-GANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭО24-CNP27(К4,5,9R)] (SEQ ID NO: 36);
ПЭО24-GANRRGLSRGCFGLKLDRIGSNSGLGC [ПЭО24-CNP27(К4,5,9R, M22N)] (SEQ ID NO: 184);
ПЭО24-PGANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭО24-Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189) и
ПЭО24-MGANRRGLSRGCFGLKLDRIGSMSGLGC [ПЭО24-Met-CNP27(K4,5,9R)] (SEQ ID NO: 194).
2. Фармацевтическая композиция, содержащая вариант CNP по п.1 и фармацевтически приемлемый эксципиент, носитель или разбавитель.
3. Композиция по п.2, которая представляет собой лиофилизированный препарат, полученный из препарата, который содержит буфер лимонная кислота/цитрат или буфер уксусная кислота/ацетат, имеющий рН примерно от 4 до примерно 6.
4. Композиция по п.3, где
(a) лиофилизированный препарат получен из препарата, который дополнительно содержит средство для изотоничности и/или наполнитель, или
(b) лиофилизированный препарат получен из препарата, который дополнительно содержит антиоксидант.
5. Способ лечения связанного с костями расстройства или дисплазии скелета, включающий введение варианта CNP пациенту,
где вариант CNP представляет собой вариант CNP по п.1, и
где связанное с костями расстройство или дисплазия скелета выбрана из группы, состоящей из остеоартрита, гипофосфатемического рахита, ахондроплазии, гипохондроплазии, низкорослости, карликовости, остеохондродисплазии, танатофорной дисплазии, несовершенного остеогенеза, ахондрогенеза, точечной эпифизарной дисплазии, гомозиготной ахондроплазии, точечной эпифизарной дисплазии, кампомелической дисплазии, наследственной летальной гипофосфатазии, перинатально-летального типа несовершенного остеогенеза, синдромов коротких ребер-полидактилии, гипохондроплазии, ризомелического типа точечной эпифизарной дисплазии, метафизарной остеодисплазии Янсена, врожденной спондилоэпифизарной дисплазии, ателостеогенеза, диастрофической дисплазии, врожденного укорочения бедра, мезомелической дисплазии Лангера, мезомелической дисплазии Нивергельта, синдрома Робиноу, синдрома Рейнхардта, акродизостоза, периферического дизостоза, дисплазии Книста, фиброхондрогенеза, синдрома Робертса, акромезомелической дисплазии, микромелии, синдрома Моркио, синдрома Книста, метатрофной дисплазии и спондилоэпиметафизарной дисплазии.
6. Способ лечения расстройства гладкой мускулатуры сосудов, включающий введение варианта CNP пациенту,
где вариант CNP представляет собой вариант CNP по п.1, и
где расстройство гладкой мускулатуры сосудов выбрано из группы, состоящей из гипертензии, рестеноза, артериосклероза, острой декомпенсированной сердечной недостаточности, застойной сердечной недостаточности, сердечного отека, почечного отека, отека печени, острой почечной недостаточности и хронической почечной недостаточности.
7. Способ основанного на рекомбинации получения варианта CNP, включающий в себя культивирование в среде клетки-хозяина, содержащей первый полинуклеотид, кодирующий полипептид варианта CNP, связанный со вторым полинуклеотидом, кодирующим отщепляемый пептид или белок, в условиях, которые приводят к экспрессии слитого полипептида, кодируемого полинуклеотидами, при этом слитый полипептид содержит полипептид варианта CNP, непосредственно связанный с отщепляемым пептидом или белком или связанный с ним опосредованно через линкер.
8. Способ по п.7, в котором отщепляемый пептид или белок выбран из группы, состоящей из гистидиновых меток, фактора транскрипции TAF12 человека, фрагментов TAF12, домена укладки гистонов TAF12, мутантов TAF12 и их фрагментов, TAF12(С/А), TAF12(D/E), TAF12(4D/4E), TAF12(6D/6E), ТАР12(10D/10E), TAF12(С/А и D/E), TAF12(С/А и 4D/4E), TAF12(С/А и 6D/6E), TAF12(С/А и 10D/10E), изомеразы кетостероидов, связывающего мальтозу белка, β-галактозидазы, глутатион-S-трансферазы, тиоредоксина, связывающего хитин домена, BMP-2, мутантов BMP-2, BMP-2(С/А) и их мутантов и фрагментов.
9. Способ по п.7, в котором клеткой-хозяином является бактериальная клетка.
10. Способ по п.7, в котором слитый полипептид экспрессируется в виде растворимого белка или тельца включения.
11. Способ по п.7, дополнительно включающий в себя выделение экспрессированного слитого полипептида из клетки-хозяина или культуральной среды.
12. Способ по п.11, дополнительно включающий в себя осуществление контакта выделенного слитого полипептида с расщепляющим агентом, выбранным из группы, состоящей из муравьиной кислоты, бромистого циана (CNBr), гидроксиламина, саморасщепляемого белка, фактора Ха, энтерокиназы, ProTEV и протеазы SUMO.
13. Способ по п.7, посредством которого получают вариант CNP, выбранный из группы, состоящей из:
R-CNP22(K4R) (Аналог AZ) (SEQ ID NO: 41);
ER-CNP22(K4R) (Аналог ВА) (SEQ ID NO: 39);
GANPR-CNP22(K4R) (Аналог CI) (SEQ ID NO: 37);
GANQQ-CNP22(K4R) (Аналог СН) (SEQ ID NO: 69);
AAWARLLQEHPNA-CNP22 (Аналог CA) (SEQ ID NO: 61);
AAWARLLQEHPNAR-CNP22 (Аналог СВ) (SEQ ID NO: 62);
DLRVDTKSRAAWAR-CNP22 (Аналог СС) (SEQ ID NO: 63);
GQPREPQVYTLPPS-CNP22 (Аналог CF) (SEQ ID NO: 79);
GERAFKAWAVARLSQ-CNP22 (Аналог СЕ) (SEQ ID NO: 81);
GHHSHEQHPHGANQQ-CNP22 (Аналог CQ) (SEQ ID NO: 76);
GQEHPNARKYKGANPK-CNP22 (Аналог CS) (SEQ ID NO: 71);
GQEHPNARKYKGANQK-CNP22 (Аналог CT) (SEQ ID NO: 130);
GAHHPHEHDTHGANQQ-CNP22 (Аналог CR) (SEQ ID NO: 77);
GQTHSSGTQSGANQQ-CNP22(K4R) (Аналог CN) (SEQ ID NO: 87);
SPKMVQGSG-CNP17-KVLRRH (Аналог CD) (SEQ ID NO: 68);
PNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-34);
GANRRGLSRGCFGLKLDRIGSMSGLGC [CNP27(K4,5,9R)] (SEQ ID NO: 36);
GANRRGLSRGCFGLKLDRIGSNSGLGC [CNP27(K4,5,9R, M22N)] (SEQ ID NO: 184);
PGANRRGLSRGCFGLKLDRIGSMSGLGC [Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189);
MGANRRGLSRGCFGLKLDRIGSMSGLGC [Met-CNP27(K4,5,9R)] (SEQ ID NO: 194);
GDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP53) (SEQ ID NO: 179);
PDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP53) (SEQ ID NO: 185);
MDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP53) (SEQ ID NO: 190);
DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP-53(M48N)] (SEQ ID NO: 180);
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-37) (SEQ ID NO: 60);
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP37(M32N)] (SEQ ID NO: 182);
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP37) (SEQ ID NO: 186);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP37) (SEQ ID NO: 192);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP37) (SEQ ID NO: 75);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [Gly-CNP37(M32N)] (SEQ ID NO: 181);
PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-Gly-CNP37) (SEQ ID NO: 145);
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-Gly-CNP37) (SEQ ID NO: 191);
GHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (HSA-CNP27) (SEQ ID NO: 144);
GHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSNSGLGC [HSA-CNP27(M22N)] (SEQ ID NO: 183);
PGHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-HSA-CNP27) (SEQ ID NO: 188); и
MGHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-HSA-CNP27) (SEQ ID NO: 193).
14. Вариант CNP, полученный согласно способу по п.7, где вариант CNP выбран из группы, состоящей из:
R-CNP22(K4R) (Аналог AZ) (SEQ ID NO: 41);
ER-CNP22(K4R) (Аналог ВА) (SEQ ID NO: 39);
GANPR-CNP22(K4R) (Аналог CI) (SEQ ID NO: 37);
GANQQ-CNP22(K4R) (Аналог СН) (SEQ ID NO: 69);
AAWARLLQEHPNA-CNP22 (Аналог СА) (SEQ ID NO: 61);
AAWARLLQEHPNAR-CNP22 (Аналог СВ) (SEQ ID NO: 62);
DLRVDTKSRAAWAR-CNP22 (Аналог CC) (SEQ ID NO: 63);
GQPREPQVYTLPPS-CNP22 (Аналог CF) (SEQ ID NO: 79);
GERAFKAWAVARLSQ-CNP22 (Аналог СЕ) (SEQ ID NO: 81);
GHHSHEQHPHGANQQ-CNP22 (Аналог CQ) (SEQ ID NO: 76);
GQEHPNARKYKGANPK-CNP22 (Аналог CS) (SEQ ID NO: 71);
GQEHPNARKYKGANQK-CNP22 (Аналог CT) (SEQ ID NO: 130);
GAHHPHEHDTHGANQQ-CNP22 (Аналог CR) (SEQ ID NO: 77);
GQTHSSGTQSGANQQ-CNP22(K4R) (Аналог CN) (SEQ ID NO: 87);
SPKMVQGSG-CNP17-KVLRRH (Аналог CD) (SEQ ID NO: 68);
PNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-34);
GANRRGLSRGCFGLKLDRIGSMSGLGC [CNP27(K4,5,9R)] (SEQ ID NO: 36);
GANRRGLSRGCFGLKLDRIGSNSGLGC [CNP27(K4,5,9R, M22N)];
PGANRRGLSRGCFGLKLDRIGSMSGLGC [Pro-CNP27(K4,5,9R)];
MGANRRGLSRGCFGLKLDRIGSMSGLGC [Met-CNP27(K4,5,9R)];
GDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP53) (SEQ ID NO: 179);
PDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP53) (SEQ ID NO: 185);
MDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP53) (SEQ ID NO: 190);
DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP-53(M48N)] (SEQ ID NO: 180);
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-37) (SEQ ID NO: 60);
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP37(M32N)] (SEQ ID NO: 182);
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP37) (SEQ ID NO: 186);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP37) (SEQ ID NO: 192);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP37) (SEQ ID NO: 75);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [Gly-CNP37(M32N)] (SEQ ID NO: 181);
PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-Gly-CNP37) (SEQ ID NO: 145);
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-Gly-CNP37) (SEQ ID NO: 191);
GHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (HSA-CNP27) (SEQ ID NO: 144);
GHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSNSGLGC [HSA-CNP27(M22N)] (SEQ ID NO: 183);
PGHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-HSA-CNP27) (SEQ ID NO: 188); и
MGHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-HSA-CNP27) (SEQ ID NO: 193).
15. Клетка-хозяин, содержащая экспрессирующий вектор, при этом вектор содержит первый полинуклеотид, кодирующий полипептид варианта CNP, связанный со вторым полинуклеотидом, кодирующим отщепляемый пептид или белок.
16. Клетка-хозяин по п.15, где клетку-хозяина культивируют в среде в условиях, подходящих для экспрессии слитого полипептида, кодируемого полинуклеотидами, при этом слитый полипептид содержит полипептид варианта CNP, непосредственно связанный с отщепляемым пептидом или белком или связанный с ним опосредованно через линкер.
17. Способ оценки влияния пептида или варианта CNP на уровень по меньшей мере одного ассоциированного с костями или хрящами биомаркера у субъекта, включающий в себя оценку уровня по меньшей мере одного ассоциированного с костями или хрящами биомаркера в биологическом образце от субъекта, которому был введен пептид или вариант CNP.
18. Способ лечения отвечающего на CNP состояния или расстройства, включающий в себя
введение пептида или варианта CNP субъекту и
мониторинг уровня по меньшей мере одного ассоциированного с костями или хрящами биомаркера у субъекта,
при этом увеличение уровня по меньшей мере одного ассоциированного с костями или хрящами биомаркера свидетельствует о терапевтическом эффекте, оказываемом пептидом или вариантом CNP на субъекта или состояние или расстройство.
19. Способ по п.17 или 18, в котором по меньшей мере один ассоциированный с костями или хрящами биомаркер выбран из группы, состоящей из CNP, цГМФ, пропептидов коллагена типа II и их фрагментов, коллагена типа II и их фрагментов, остеокальцина, ядерного антигена пролиферирующих клеток (PCNA), пропептидов проколлагена типа I (PINP) и их фрагментов, коллагена типа I и его фрагментов, аггрекан-хондроитинсульфата и щелочной фосфатазы.
20. Способ по п.17 или 18, в котором пептид или вариант CNP выбран из группы, состоящей из:
R-CNP22(K4R) (Аналог AZ) (SEQ ID NO: 41);
GANRR-CNP22(K4R)(аналог AY) (SEQ ID NO: 36);
AAWARLLQEHPNA-CNP22 (Аналог СА) (SEQ ID NO: 61);
AAWARLLQEHPNAR-CNP22 (Аналог СВ) (SEQ ID NO: 62);
DLRVDTKSRAAWAR-CNP22 (Аналог СС) (SEQ ID NO: 63);
GQPREPQVYTLPPS-CNP22 (Аналог CF) (SEQ ID NO: 79);
GERAFKAWAVARLSQ-CNP22 (Аналог СЕ) (SEQ ID NO: 81);
GHHSHEQHPHGANQQ-CNP22 (Аналог CQ) (SEQ ID NO: 76);
GQEHPNARKYKGANPK-CNP22 (Аналог CS) (SEQ ID NO: 71);
GQEHPNARKYKGANQK-CNP22 (Аналог CT) (SEQ ID NO: 130);
GAHHPHEHDTHGANQQ-CNP22 (Аналог CR) (SEQ ID NO: 77);
GQTHSSGTQSGANQQ-CNP22(K4R) (Аналог CN) (SEQ ID NO: 87);
SPKMVQGSG-CNP17-KVLRRH (Аналог CD) (SEQ ID NO: 68);
GDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP53) (SEQ ID NO: 179);
PDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP53) (SEQ ID NO: 185);
MDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP53) (SEQ ID NO: 190);
DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP-53(M48N)] (SEQ ID NO: 180);
DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-53) (SEQ ID NO: 4);
LRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-52) (SEQ ID NO: 146);
RVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-51) (SEQ ID NO: 147);
VDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-50) (SEQ ID NO: 148);
DTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-49) (SEQ ID NO: 149);
TKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-48) (SEQ ID NO: 150);
KSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-47) (SEQ ID NO: 151);
SRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-46) (SEQ ID NO: 152);
RAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-45) (SEQ ID NO: 153);
AAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-44) (SEQ ID NO: 154);
AWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-43) (SEQ ID NO: 155);
WARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-42) (SEQ ID NO: 156);
ARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-41) (SEQ ID NO: 157);
RLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-40) (SEQ ID NO: 158);
LLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-39) (SEQ ID NO: 159);
LQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-38) (SEQ ID NO: 160);
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-37) (SEQ ID NO: 60);
EHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-36) (SEQ ID NO: 161);
HPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-35) (SEQ ID NO: 162);
PNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-34) (SEQ ID NO: 163);
NARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-33) (SEQ ID NO: 164);
ARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-32) (SEQ ID NO: 165);
RKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-31) (SEQ ID NO: 166);
KYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-30) (SEQ ID NO: 167);
YKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-29) (SEQ ID NO: 168);
KGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-28) (SEQ ID NO: 169);
GANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-27) (SEQ ID NO: 170);
ANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-26) (SEQ ID NO: 171);
NKKGLSKGCFGLKLDRIGSMSGLGC (CNP-25) (SEQ ID NO: 172);
KKGLSKGCFGLKLDRIGSMSGLGC (CNP-24) (SEQ ID NO: 173);
KGLSKGCFGLKLDRIGSMSGLGC (CNP-23) (SEQ ID NO: 174);
GLSKGCFGLKLDRIGSMSGLGC (CNP-22) (SEQ ID NO: 1);
LSKGCFGLKLDRIGSMSGLGC (CNP-21) (SEQ ID NO: 175);
SKGCFGLKLDRIGSMSGLGC (CNP-20) (SEQ ID NO: 176);
KGCFGLKLDRIGSMSGLGC (CNP-19) (SEQ ID NO: 177);
GCFGLKLDRIGSMSGLGC (CNP-18) (SEQ ID NO: 178);
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [CNP37(M32N)] (SEQ ID NO: 181);
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-CNP37) (SEQ ID NO: 186);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-CNP37) (SEQ ID NO: 191);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Gly-CNP37) (SEQ ID NO: 75);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC [Gly-CNP37(M32N)] (SEQ ID NO: 181);
PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-Gly-CNP37) (SEQ ID NO: 145);
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-Gly-CNP37) (SEQ ID NO: 191);
GHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (HSA-CNP27) (SEQ ID NO: 144);
GHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSNSGLGC [HSA-CNP27(M22N)] (SEQ ID NO: 183);
PGHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-HSA-CNP27) (SEQ ID NO: 188);
MGHKSEVAHRFKGANKKGLSKGCFGLKLDRIGSMSGLGC (Met-HSA-CNP27) (SEQ ID NO: 193);
GANRRGLSRGCFGLKLDRIGSMSGLGC [CNP27(K4,5,9R)] (SEQ ID NO: 36);
GANRRGLSRGCFGLKLDRIGSNSGLGC [CNP27(K4,5,9R, M22N)] (SEQ ID NO: 184);
PGANRRGLSRGCFGLKLDRIGSMSGLGC [Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189);
MGANRRGLSRGCFGLKLDRIGSMSGLGC [Met-CNP27(K4,5,9R)] (SEQ ID NO: 194);
PEG1K-CNP22 (SEQ ID NO: 1);
PEO12-CNP22 (SEQ ID NO: 1);
PEO24-CNP22 (SEQ ID NO: 1);
PEO12-R-CNP22(K4R) (SEQ ID NO: 41);
PEO24-R-CNP22(K4R) (SEQ ID NO: 41);
PEO12-ER-CNP22(K4R) (SEQ ID NO: 39);
PEO24-ER-CNP22(K4R) (SEQ ID NO: 39);
PEO12-GANPR-CNP22(K4R) (SEQ ID NO: 37);
PEO24-GANPR-CNP22(K4R) (SEQ ID NO: 37);
PEO12-GANQQ-CNP22(K4R) (SEQ ID NO: 69);
PEO24-GANQQ-CNP22(K4R) (SEQ ID NO: 69);
PEG1K-GANRRGLSRGCFGLKLDRIGSMSGLGC [PEG1K-CNP27(К4,5,9R)] (SEQ ID NO: 36);
PEG1K-GANRRGLSRGCFGLKLDRIGSNSGLGC [PEG1K-CNP27(К4,5,9R, M22N)] (SEQ ID NO: 184);
PEG1K-PGANRRGLSRGCFGLKLDRIGSMSGLGC [PEG1K-Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189);
PEG1K-MGANRRGLSRGCFGLKLDRIGSMSGLGC [PEG1K-Met-CNP27(K4,5,9R)] (SEQ ID NO: 194);
PEO12-GANRRGLSRGCFGLKLDRIGSMSGLGC [PEO12-CNP27(К4,5,9R)] (SEQ ID NO: 36);
PEO12-GANRRGLSRGCFGLKLDRIGSNSGLGC [PEO12-CNP27(К4,5,9R, M22N)] (SEQ ID NO: 184);
PEO12-PGANRRGLSRGCFGLKLDRIGSMSGLGC [PEO12-Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189);
PEO12-MGANRRGLSRGCFGLKLDRIGSMSGLGC [PEO12-Met-CNP27(K4,5,9R)] (SEQ ID NO: 194);
PEO24-GANRRGLSRGCFGLKLDRIGSMSGLGC [PEO24-CNP27(К4,5,9R)] (SEQ ID NO: 36);
PEO24-GANRRGLSRGCFGLKLDRIGSNSGLGC [PEO24-CNP27(К4,5,9R, M22N)] (SEQ ID NO: 184);
PEO24-PGANRRGLSRGCFGLKLDRIGSMSGLGC [PEO24-Pro-CNP27(K4,5,9R)] (SEQ ID NO: 189); и
PEO24-MGANRRGLSRGCFGLKLDRIGSMSGLGC [PEO24-Met-CNP27(K4,5,9R)] (SEQ ID NO: 194).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18011209P | 2009-05-20 | 2009-05-20 | |
US61/180,112 | 2009-05-20 | ||
US25456309P | 2009-10-23 | 2009-10-23 | |
US61/254,563 | 2009-10-23 | ||
PCT/US2010/035586 WO2010135541A2 (en) | 2009-05-20 | 2010-05-20 | Variants of c-type natriuretic peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011152007A true RU2011152007A (ru) | 2013-06-27 |
RU2573911C2 RU2573911C2 (ru) | 2016-01-27 |
Family
ID=43124672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011152007/10A RU2573911C2 (ru) | 2009-05-20 | 2010-05-20 | Варианты натрийуретического пептида с-типа |
Country Status (25)
Country | Link |
---|---|
US (6) | US8198242B2 (ru) |
EP (3) | EP3175863B1 (ru) |
JP (1) | JP5718909B2 (ru) |
KR (5) | KR101831923B1 (ru) |
CN (1) | CN102481330B (ru) |
AR (1) | AR078044A1 (ru) |
AU (1) | AU2010249802B2 (ru) |
BR (2) | BRPI1012783B1 (ru) |
CA (1) | CA2758581C (ru) |
CL (1) | CL2011002430A1 (ru) |
DK (2) | DK3175863T3 (ru) |
ES (2) | ES2608457T3 (ru) |
FR (1) | FR22C1004I2 (ru) |
HK (1) | HK1168279A1 (ru) |
HR (2) | HRP20220057T1 (ru) |
HU (3) | HUE032582T2 (ru) |
IL (1) | IL215287A (ru) |
MX (1) | MX2011012277A (ru) |
PE (1) | PE20120792A1 (ru) |
PL (2) | PL2432489T3 (ru) |
PT (2) | PT2432489T (ru) |
RU (1) | RU2573911C2 (ru) |
TW (1) | TWI471137B (ru) |
WO (1) | WO2010135541A2 (ru) |
ZA (1) | ZA201107087B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2794515C2 (ru) * | 2015-07-30 | 2023-04-19 | Байомарин Фармасьютикал Инк. | Применение вариантов натрийуретического пептида c-типа для лечения скелетной дисплазии |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1759001T3 (pl) | 2004-04-21 | 2011-09-30 | Alexion Pharma Inc | Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości |
EP3175863B1 (en) | 2009-05-20 | 2021-12-01 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
KR101226165B1 (ko) | 2009-07-23 | 2013-01-24 | 가부시키가이샤 이기스 | 피부 외용제 조성물 |
KR101229546B1 (ko) * | 2009-08-27 | 2013-02-05 | 쿄고 엔도 | 비염 치료제 |
JP5986986B2 (ja) | 2010-04-30 | 2016-09-06 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 基質石灰化障害を治療する方法、組成物、およびキット |
CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
EP2678002A2 (en) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
EP2741762A4 (en) * | 2011-07-27 | 2015-04-15 | NATRIURETIC PEPTIDE COMPOSITIONS AND PREPARATION METHODS | |
US20130244937A1 (en) * | 2011-09-02 | 2013-09-19 | Nile Therapeutics, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
CA2852874A1 (en) | 2011-10-19 | 2013-04-25 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
EP3088416B1 (en) * | 2011-12-23 | 2019-02-27 | Mayo Foundation for Medical Education and Research | Assessing renal structural alterations and outcomes |
JPWO2013161895A1 (ja) * | 2012-04-25 | 2015-12-24 | 第一三共株式会社 | 骨修復促進剤 |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2014063102A1 (en) * | 2012-10-19 | 2014-04-24 | Cornell University | Biomimetic boundary lubricants for articular cartilage |
KR20150124941A (ko) * | 2013-03-10 | 2015-11-06 | 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 | 골 계통 질환 치료약 및 그 용도 |
CN103159847B (zh) * | 2013-04-12 | 2014-05-28 | 叶亮 | 一种利钠肽及其基因与用途 |
AU2015206515B2 (en) | 2014-01-15 | 2019-12-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cartilage targeting agents and their use |
US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
MX2017007392A (es) | 2014-12-05 | 2019-01-24 | Alexion Pharma Inc | Tratamiento de convulsiones con fosfatasa alcalina recombinante. |
AU2016205968A1 (en) * | 2015-01-09 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs |
US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
FI3328416T3 (fi) * | 2015-07-30 | 2024-03-26 | Biomarin Pharm Inc | C-tyypin natriureettisten peptidivarianttien käyttö luuston dysplasian hoidossa |
US20190119325A1 (en) * | 2015-07-31 | 2019-04-25 | Igisu Co., Ltd. | Cnp cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide |
CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
RU2759679C2 (ru) * | 2015-12-08 | 2021-11-16 | Байомарин Фармасьютикал Инк. | Применение вариантов натрийуретического пептида типа с для лечения остеоартрита |
MX2018008061A (es) * | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
US11413351B2 (en) * | 2016-01-08 | 2022-08-16 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with carrier attachment at the ring moiety |
MY195190A (en) * | 2016-01-08 | 2023-01-11 | Ascendis Pharma Growth Disorders As | Controlled-Release Cnp Agonists With Increased Nep Stability |
WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
US11389510B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
AU2017205694B2 (en) * | 2016-01-08 | 2022-05-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN |
WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
CA3019726A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
AU2017295938C1 (en) * | 2016-07-13 | 2021-10-07 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
BR112019005351A2 (pt) | 2016-09-29 | 2019-06-11 | Ascendis Pharma Growth Disorders As | terapia combinada com agonistas de cnp de liberação controlada |
US20180194824A1 (en) * | 2016-12-14 | 2018-07-12 | University Of Iowa Research Foundation | Musclin peptides and methods of use thereof |
US20200030414A1 (en) * | 2017-01-24 | 2020-01-30 | Daiichi Sankyo Company, Limited | Therapeutic agent for short stature |
WO2018163131A1 (en) | 2017-03-10 | 2018-09-13 | Quiapeg Pharmaceuticals Ab | Releasable conjugates |
KR20190129058A (ko) | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
KR20210057130A (ko) | 2018-09-12 | 2021-05-20 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 glp-1 컨쥬게이트 |
CA3129352A1 (en) | 2019-02-11 | 2020-08-20 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
CN113966345A (zh) | 2019-06-12 | 2022-01-21 | 诺华股份有限公司 | 利钠肽受体1抗体及使用方法 |
CN114423447A (zh) * | 2019-08-12 | 2022-04-29 | 生物马林药物股份有限公司 | 用于延释组合物的疏水性肽盐 |
EP4031183A1 (en) * | 2019-09-16 | 2022-07-27 | BioMarin Pharmaceutical Inc. | Cnp variants and conjugates thereof |
WO2022115563A1 (en) * | 2020-11-25 | 2022-06-02 | Prolynx Llc | Extended release hydrogel conjugates of c-natriuretic peptides |
RU2763661C2 (ru) * | 2021-03-31 | 2021-12-30 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ терапии и профилактики прогрессирования хронической почечной недостаточности |
CA3226388A1 (en) | 2021-07-09 | 2023-01-12 | Biomarin Pharmaceutical Inc. | C-type natriuretic peptide variants to treat skeletal dysplasia in children |
TW202334188A (zh) * | 2021-12-07 | 2023-09-01 | 美商拜奧馬林製藥公司 | Cnp療法 |
WO2023110758A1 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
WO2023117855A1 (en) * | 2021-12-20 | 2023-06-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment |
WO2023173086A1 (en) * | 2022-03-11 | 2023-09-14 | Avirmax Biopharma Inc. | Compositions and methods for expressing therapeutics |
WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0478797T3 (da) | 1990-04-20 | 1995-06-26 | Hisayuki Matsuo | Nyt fysiologisk aktivt peptid stammende fra gris |
JP2930380B2 (ja) | 1990-07-13 | 1999-08-03 | 壽之 松尾 | ブタ由来新規生理活性ペプチド(cnp―53) |
JP3026351B2 (ja) * | 1990-07-13 | 2000-03-27 | 壽之 松尾 | ブタcnp遺伝子及び前駆体蛋白 |
JP3026354B2 (ja) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトcnp遺伝子及び前駆体蛋白 |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP2809533B2 (ja) * | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Cnp類似体ペプチド |
AU6360394A (en) | 1993-03-03 | 1994-09-26 | Mayo Foundation For Medical Education And Research | Vasonatrin peptide and analogs thereof |
US5846932A (en) | 1993-11-12 | 1998-12-08 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
CA2249446C (en) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
WO1999007701A1 (en) | 1997-08-05 | 1999-02-18 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
US6136040A (en) * | 1998-03-05 | 2000-10-24 | Washington University | Animal model with disrupted FGF-9 gene |
IL125958A0 (en) * | 1998-08-27 | 1999-04-11 | Yeda Res & Dev | Animal model for fibroblast growth factor receptor associated chondrodysplasia |
WO2000061631A1 (en) | 1999-04-12 | 2000-10-19 | Astrazeneca Ab | Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor |
US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6407211B1 (en) * | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
JP2002178279A (ja) | 2000-12-12 | 2002-06-25 | Ulvac Japan Ltd | 基板搬送方法 |
IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
AU2003214214A1 (en) * | 2002-03-18 | 2003-10-08 | Scios Inc. | Method for treating congestive heart failure |
US6861236B2 (en) * | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
WO2004043396A2 (en) | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
ATE490469T1 (de) * | 2003-06-17 | 2010-12-15 | Otago Innovation Ltd | Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden |
EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
CA2786794C (en) * | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
JP4825667B2 (ja) | 2004-03-31 | 2011-11-30 | 一和 中尾 | 関節炎症治療剤又は予防剤 |
KR20070007842A (ko) * | 2004-03-31 | 2007-01-16 | 카즈와 나카오 | 신장증가용 조성물 |
JP2005292718A (ja) | 2004-04-05 | 2005-10-20 | Furukawa Electric Co Ltd:The | 光導波路、光導波路モジュールおよび光導波路の作成方法 |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
ATE496060T1 (de) * | 2004-07-15 | 2011-02-15 | Univ Queensland | Proteinartige verbindungen und anwendungen davon |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
JP2010530222A (ja) | 2007-06-06 | 2010-09-09 | べーリンガー インゲルハイム インターナショナル ゲーエムベーハー | ナトリウム利尿融合タンパク質 |
EP2171053B1 (en) * | 2007-07-20 | 2014-04-23 | Mayo Foundation for Medical Education and Research | Natriuretic polypeptides |
JP2010539056A (ja) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのcnp−22単独、またはフィサレミンとの組合せの使用 |
TWI367213B (en) * | 2007-11-21 | 2012-07-01 | Biomarin Pharm Inc | Variants of c-type natriuretic peptide |
US20090163421A1 (en) | 2007-12-19 | 2009-06-25 | Ekr Therapeutics, Inc. | Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations |
LT2237799T (lt) | 2008-02-01 | 2019-07-25 | Ascendis Pharma A/S | Provaistas, apimantis besiskaidantį linkerį |
EP2277890B1 (en) * | 2008-05-23 | 2016-01-06 | Daiichi Sankyo Company, Limited | Peptide capable of extending half-life of peptide of interest in plasma |
EP2334334A1 (en) | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
EP3175863B1 (en) | 2009-05-20 | 2021-12-01 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
-
2010
- 2010-05-20 EP EP16192229.9A patent/EP3175863B1/en active Active
- 2010-05-20 KR KR1020117030424A patent/KR101831923B1/ko active IP Right Grant
- 2010-05-20 HR HRP20220057TT patent/HRP20220057T1/hr unknown
- 2010-05-20 RU RU2011152007/10A patent/RU2573911C2/ru active
- 2010-05-20 EP EP10778389.6A patent/EP2432489B1/en active Active
- 2010-05-20 AU AU2010249802A patent/AU2010249802B2/en active Active
- 2010-05-20 DK DK16192229.9T patent/DK3175863T3/da active
- 2010-05-20 PL PL10778389T patent/PL2432489T3/pl unknown
- 2010-05-20 KR KR1020187004835A patent/KR102033680B1/ko active IP Right Grant
- 2010-05-20 TW TW99116187A patent/TWI471137B/zh active
- 2010-05-20 BR BRPI1012783-6A patent/BRPI1012783B1/pt active IP Right Grant
- 2010-05-20 ES ES10778389.6T patent/ES2608457T3/es active Active
- 2010-05-20 HU HUE10778389A patent/HUE032582T2/en unknown
- 2010-05-20 EP EP21211450.8A patent/EP4029512A1/en active Pending
- 2010-05-20 AR ARP100101761A patent/AR078044A1/es active IP Right Grant
- 2010-05-20 MX MX2011012277A patent/MX2011012277A/es active IP Right Grant
- 2010-05-20 PE PE2011001729A patent/PE20120792A1/es active IP Right Grant
- 2010-05-20 HU HUE16192229A patent/HUE057174T2/hu unknown
- 2010-05-20 JP JP2012512035A patent/JP5718909B2/ja active Active
- 2010-05-20 CA CA2758581A patent/CA2758581C/en active Active
- 2010-05-20 PT PT107783896T patent/PT2432489T/pt unknown
- 2010-05-20 DK DK10778389.6T patent/DK2432489T3/en active
- 2010-05-20 KR KR1020237032637A patent/KR20230142644A/ko active Application Filing
- 2010-05-20 PL PL16192229T patent/PL3175863T3/pl unknown
- 2010-05-20 BR BR122019026832-0A patent/BR122019026832B1/pt active IP Right Grant
- 2010-05-20 WO PCT/US2010/035586 patent/WO2010135541A2/en active Application Filing
- 2010-05-20 PT PT161922299T patent/PT3175863T/pt unknown
- 2010-05-20 US US12/784,117 patent/US8198242B2/en active Active
- 2010-05-20 ES ES16192229T patent/ES2904360T3/es active Active
- 2010-05-20 KR KR1020217006359A patent/KR20210027537A/ko not_active IP Right Cessation
- 2010-05-20 KR KR1020197029927A patent/KR102225470B1/ko active IP Right Grant
- 2010-05-20 CN CN201080023189.6A patent/CN102481330B/zh active Active
-
2011
- 2011-09-21 IL IL215287A patent/IL215287A/en active IP Right Grant
- 2011-09-28 ZA ZA2011/07087A patent/ZA201107087B/en unknown
- 2011-09-30 CL CL2011002430A patent/CL2011002430A1/es unknown
-
2012
- 2012-05-08 US US13/466,672 patent/US8598121B2/en not_active Ceased
- 2012-09-14 HK HK12109054.0A patent/HK1168279A1/zh unknown
-
2015
- 2015-01-23 US US14/604,262 patent/USRE46707E1/en active Active
- 2015-03-17 US US14/660,488 patent/US20160256553A1/en not_active Abandoned
-
2016
- 2016-10-24 US US15/332,793 patent/US20170051033A1/en not_active Abandoned
- 2016-12-19 HR HRP20161739TT patent/HRP20161739T1/hr unknown
-
2017
- 2017-07-11 US US15/646,822 patent/USRE48267E1/en active Active
-
2022
- 2022-01-20 HU HUS2200004C patent/HUS2200004I1/hu unknown
- 2022-01-28 FR FR22C1004C patent/FR22C1004I2/fr active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2794515C2 (ru) * | 2015-07-30 | 2023-04-19 | Байомарин Фармасьютикал Инк. | Применение вариантов натрийуретического пептида c-типа для лечения скелетной дисплазии |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011152007A (ru) | Варианты натрийуретического пептида с-типа | |
JP2012527244A5 (ru) | ||
DK2277890T3 (en) | Peptide which is able to extend the half-life of a peptide of interest in the plasma | |
US9969788B2 (en) | Methods of treating damaged cartilage tissue using growth factors fused to heparin binding sequences | |
CN106432510A (zh) | 用于治疗代谢疾病的双功能蛋白 | |
JP2930380B2 (ja) | ブタ由来新規生理活性ペプチド(cnp―53) | |
KR20120127729A (ko) | 엑센딘-4 및 이의 유사체의 융합 단백질, 제조방법 및 이의 용도 | |
KR20190022943A (ko) | 리소좀 축적증의 개선된 치료를 위해 재조합 리소좀 효소상에 표적화 펩티드를 커플링시키는 방법 | |
CA2206509A1 (en) | Novel hedgehog-derived polypeptides | |
JP2977159B2 (ja) | カエル由来新規生理活性ペプチド(カエルcnp) | |
CN110305223A (zh) | 重组串联融合蛋白制备目标多肽的方法 | |
JP2019142889A (ja) | 化学架橋剤 | |
US20150283214A1 (en) | Chimeric fibronectin matrix mimetics and uses thereof | |
CN116333094B (zh) | 一种重组人源化I型胶原蛋白α1及表达载体和应用 | |
Miura et al. | Interaction between myostatin and extracellular matrix components | |
CN114920826B (zh) | Ⅲ型类人胶原蛋白及其编码基因、表达载体和重组酵母菌 | |
Davoodi et al. | The Simpson–Golabi–Behmel syndrome causative Glypican‐3, binds to and inhibits the dipeptidyl peptidase activity of CD26 | |
CN116948013A (zh) | 重组小分子胶原蛋白及其表达系统与制备方法 | |
CN110590905A (zh) | 一种降血糖六肽 | |
Makino et al. | Semisynthesis of human ghrelin: Condensation of a Boc‐protected recombinant peptide with a synthetic O‐acylated fragment | |
KR101871805B1 (ko) | 재조합 상피세포성장인자의 제조방법 | |
CN102952192A (zh) | 一种含有Exendin-4的融合蛋白及其用途 | |
JPH10338643A (ja) | Acsfアンタゴニストの組成物 | |
Xiong | New insights into structure and function of type I collagen | |
TW202346323A (zh) | 具有改善的生物穩定性的glp—1及升糖素雙重激動肽 |